{"id":"7f04c5af1657","type":"article","url":"https://hartvaat.nl/2026/01/11/zeventien-jaar-voor-verandering-doorbreken-de-2025-esc-eas-dyslipidemierichtlijn/","title":"Zeventien jaar voor verandering: doorbreken de 2025 ESC/EAS-dyslipidemierichtlijnen de cyclus?","title_en":"Seventeen years to change practice: will the 2025 ESC/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["dyslipidemie","ezetimibe","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pelacarsen","statines"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00002-X/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00002-X/fulltext","authors":["Kausik K. Ray","Florian Kronenberg"],"significance":7,"published":"2026-01-11","source_date":"2026-01-11","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/esc-richtlijn-dyslipidemie-2019/"],"congress":"","summary_en":"This commentary on the 2025 ESC/EAS dyslipidemia guideline update discussed the modernized recommendations for risk assessment and lipid-lowering therapy, including expanded indications for non-statin treatments and lower LDL targets.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De 2025 Focused Update van de ESC/EAS-dyslipidemierichtlijnen moderniseert aanbevelingen over risicobeoordeling, lipidenverlagende behandeling en lipoproteïne(a). Dit commentaar bespreekt of de richtlijnen eindelijk de Sisyfus-cyclus doorbreken.","abstract_original":"The 2025 Focused Update of the ESC/EAS Guidelines for the Management of Dyslipidemias modernizes guidelines on risk assessment, lipid-lowering treatments, and lipoprotein(a) management, and it incorporates modifications based on new data. The adopted SCORE2 and SCORE2-OP algorithms, which take into consideration both fatal and non-fatal events and extend risk prediction up to age 89, are crucial because they update cardiovascular risk assessment and rectify past underestimation of risk for women and younger persons."}